Goodwin Procter·PHARMA / BIOTECH
Teva Licenses Two Samsung Bioepis Biosimilars for U.S. Commercialization
Teva announced on November 3, 2026 a licensing agreement with Samsung Bioepis to commercialize RENFLEXIS (infliximab-abda) and ETICOVO (etanercept-ykro) in the United States.
tevasamsung-bioepisbiosimilarslicensing-agreementinfliximabetanerceptcommercialization-deals
Read the original firm alert → Wednesday, November 11, 2026